Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance

Adam Scott Feldman, MD, MPH
Published: Tuesday, Oct 10, 2017



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.

In a study investigating active surveillance, pathologic progression was the main reason that men progressed to treatment, states Feldman. On a future biopsy, these men had an increased volume of disease or an increase of Gleason score.

Other reasons men progressed to treatment included a higher prostate-specific antigen (PSA) density, which correlates with higher volume of disease, explains Feldman.



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.

In a study investigating active surveillance, pathologic progression was the main reason that men progressed to treatment, states Feldman. On a future biopsy, these men had an increased volume of disease or an increase of Gleason score.

Other reasons men progressed to treatment included a higher prostate-specific antigen (PSA) density, which correlates with higher volume of disease, explains Feldman.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x